PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
Open Access
- 17 November 2011
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (12), 1850-1855
- https://doi.org/10.1038/bjc.2011.493
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [11C]gefitinibNuclear Medicine and Biology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomographyEuropean Journal of Cardio-Thoracic Surgery, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- PET scan imaging in oncologyEuropean Journal of Cancer, 2003